Therefore, continuing efforts are needed to develop GLI inhibitors that can be safely translated into clinical use and could be combined to target FLT3/PI3K/GLI in the treatment of FLT3-mutated AML patients. The gene discussed is FLT3; the disease is acute myeloid leukemia.